Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks

Srdan Verstovsek, MD, Ruben A. Mesa, Lynda M Foltz, MD, Vikas Gupta, MD MRCP, MRCPath, John O. Mascarenhas, MD MS, Ellen K. Ritchie, MD, Ronald Hoffman, MD, Richard T. Silver, MD, Marina Kremyanskaya, MDPhD, Olga Pozdnyakova, MD, Robert P. Hasserjian, MD, Elizabeth Trehu, MD, Mohamed E Salama, MD, Hagop M Kantarjian, MD, Jason Gotlib, MD

Blood (2015) 126 (23): 56.

https://doi.org/10.1182/blood.V126.23.56.56

Published: 2015

Journal Articles

Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF)

Haifa Kathrin Al-Ali, MD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Julian Perez Ronco, MD MBA, Lynda M Foltz, MD FRCP

Blood (2014) 124 (21): 4583.

https://doi.org/10.1182/blood.V124.21.4583.4583

Published: 2014

Journal Articles

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update

Bruno Martino, Philipp le Coutre, MD, Martin Griesshammer, MD, Thomas Illmer, MD, Rudolf Schlag, Cornelius F. Waller, MD, Anna Marina Liberati, Philippe Schafhausen, MD, Renato S Tavares, MD, Alessandro M. Vannucchi, MD, Pilar Giraldo, MD PhD, Lynda M Foltz, MD FRCP, Pia Raanani, MD, Vikas Gupta, MD FRCP, FRCPath, Bayane Tannir, Julian Perez Ronco, MD, Jaggannath Ghosh, Haifa Kathrin Al-Ali, MD

Blood (2014) 124 (21): 3197.

https://doi.org/10.1182/blood.V124.21.3197.3197

Published: 2014

Journal Articles

Safety and Efficacy of Ruxolitinib Retreatment after Treatment Interruption in Patients Enrolled in an Open-Label, Multicenter, Expanded-Access Study in Myelofibrosis

Vikas Gupta, MD FRCP, FRCPath, Renato S Tavares, MD, Martin Griesshammer, MD, Lynda M Foltz, MD FRCP, Pia Raanani, MD, Pilar Giraldo, Haifa Kathrin Al-Ali, MD, Bruno Martino, MD, Bayane Tannir, Julian Perez Ronco, MD, Jagannath Ghosh, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 5567.

https://doi.org/10.1182/blood.V124.21.5567.5567

Published: 2014

Journal Articles

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results

Srdan Verstovsek, MD PhD, Ruben A. Mesa, MD, Lynda M Foltz, MD, Vikas Gupta, MD FRCP, FRCPath, John O Mascarenhas, MD MS, Ellen K. Ritchie, MD, Ronald Hoffman, MD, Richard T. Silver, MD, Marina Kremyanskaya, MDPhD, Olga Pozdnyakova, MD PhD, Robert P Hasserjian, MD, Elizabeth Trehu, MD, Hagop M. Kantarjian, MD, Jason R. Gotlib, MD

Blood (2014) 124 (21): 713.

https://doi.org/10.1182/blood.V124.21.713.713

Published: 2014

Journal Articles

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis

John O Mascarenhas, MD MS, Moshe Talpaz, Vikas Gupta, MD FRCP, FRCPath, Lynda M Foltz, MD FRCP, Michael R Savona, MD, Ron Paquette, MD, Robert Turner, MD, Paul Coughlin, PhD MBBS, Elliott Winton, MD, Deborah Hunter, PhD, Albert Assad, MD, Jason Clark, PhD, Peter O'Neill, MBA, CCRP, Ronald Hoffman, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 714.

https://doi.org/10.1182/blood.V124.21.714.714

Published: 2014

Journal Articles

Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis (MF)

Martin Griesshammer, MD, Alessandro M. Vannucchi, MD, Philipp le Coutre, MD, Renato S Tavares, MD, Haifa Kathrin Al-Ali, MD, Pia Raanani, MD, Vikas Gupta, MD FRCP, FRCPath, Lynda M Foltz, MD FRCP, Pilar Giraldo, Catherine Bouard, Julian Perez Ronco, MD MBA, Jagannath Ghosh, Bruno Martino, MD

Blood (2014) 124 (21): 1859.

https://doi.org/10.1182/blood.V124.21.1859.1859

Published: 2014

Journal Articles

Barriers To Diagnosis In Myeloproliferative Neoplasms

Raymond H L Yip, Lynda M Foltz, MD, FRCP(C)

Blood (2013) 122 (21): 5248.

https://doi.org/10.1182/blood.V122.21.5248.5248

Published: 2013

Journal Articles

Improved Survival with Iron Chelation Therapy for Lower IPSS Risk MDS Appears to Have a Stronger Association in Patients with a Non-RARS Diagnosis

Heather A Leitch, MD, PhD, FRCPC, Christopher Chan, Chantal S Leger, MD, FRCP(C), Lynda M Foltz, MD, FRCP(C), Khaled M Ramadan, MBBCH, MRCPI, FRCPath, FRCP, FRCPC, Linda M Vickars, MD, FRCP(C)

Blood (2011) 118 (21): 1732.

https://doi.org/10.1182/blood.V118.21.1732.1732

Published: 2011

Journal Articles

Clinical Features, Treatment, and Outcome of Severe HIV-Associated Immune Thrombocytopenic Purpura In the HAART Era

Kimberley LS Ambler, MD, FRCP(C), Linda M Vickars, MD, FRCP(C), Chantal S Leger, MD, FRCP(C), Lynda M Foltz, MD, FRCP(C), Julio SG Montaner, MD, FRCPC, FCCP, Marianne Harris, MD, FRCPC, Heather A Leitch, MD, PhD, FRCP(C)

Blood (2010) 116 (21): 2522.

https://doi.org/10.1182/blood.V116.21.2522.2522

Published: 2010

Journal Articles

Diagnosis and Treatment of Essential Thrombocythemia: Assessment of Current Clinical Practice.

Vivian H Y Lee, BSc, Erica Peterson, M.Sc., M.D., Leslie Zypchen, MD, Lynda M Foltz, MD

Blood (2009) 114 (22): 1903.

https://doi.org/10.1182/blood.V114.22.1903.1903

Published: 2009

Journal Articles

Thrombotic Complications and Risk of Myeloid Transformation in 164 Elderly Patients with Essential Thrombocythemia.

Erica Peterson, M.Sc., M.D., Leslie Zypchen, MD, Janet Nitta, Jonathan Berkowitz, M.Sc., Ph.D., Lynda M Foltz, MD

Blood (2009) 114 (22): 2916.

https://doi.org/10.1182/blood.V114.22.2916.2916

Published: 2009

Journal Articles

A Scoring System Based on Clinical, Blood Count and Immunophenotypic Data Can Predict the Risk of Disease Progression in Patients with Chronic Lymphocytic Leukemia

Sina Alipour, BSc, Heather Leitch, MD, PhD, Linda M Vickars, MD, Lynda M Foltz, MD, Paul F Galbraith, MD, Chantal S Leger, MD, Khaled M Ramadan, MBBCh, FRCPI, FRCPath

Blood (2008) 112 (11): 4185.

https://doi.org/10.1182/blood.V112.11.4185.4185

Published: 2008

Journal Articles

CD38 Expression above 20% Predicts Disease Progression in Chronic Lymphocytic Leukemia and Is a Useful Prognostic Marker Where Cytogenetic and Molecular Markers Are Not Available

Sina Alipour, BSc, Heather Leitch, MD, PhD, Linda M Vickars, MD, Lynda M Foltz, MD, Paul F Galbraith, MD, Chantal S Leger, MD, Khaled M Ramadan, MBBCh, FRCPI, FRCPath

Blood (2008) 112 (11): 4190.

https://doi.org/10.1182/blood.V112.11.4190.4190

Published: 2008

Journal Articles

Richter Transformation of Chronic Lymphocytic Leukemia: Incidence, Risk Factors and Outcome

Sina Alipour, BSc, Heather Leitch, MD, PhD, Linda M Vickars, MD, Lynda M Foltz, MD, Paul F Galbraith, MD, Chantal S Leger, MD, Khaled M Ramadan, MBBCh, FRCPI, FRCPath

Blood (2008) 112 (11): 3179.

https://doi.org/10.1182/blood.V112.11.3179.3179

Published: 2008

Journal Articles

Improved Survival in Red Blood Cell Transfusion Dependent Patients with Primary Myelofibrosis (PMF) Receiving Iron Chelation Therapy.

Heather Leitch, MD, PhD, Hatoon Ezzat, MBBS, Meaghan D Rollins, BHK, Trisha A Goodman, BHK, Chantal S Leger, MD, Dominic HC Wong, BSc, Khaled M Ramadan, MB, Lynda M Foltz, MD, Linda M Vickars, MD

Blood (2008) 112 (11): 1748.

https://doi.org/10.1182/blood.V112.11.1748.1748

Published: 2008

Journal Articles

Who Actually Detects Relapse in Hodgkin Lymphoma: Patient or Physician?.

Lynda M. Foltz, MD, Kevin W. Song, MD, Joseph M. Connors, MD

Blood (2004) 104 (11): 3124.

https://doi.org/10.1182/blood.V104.11.3124.3124

Published: 2004

NARROW

PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks

Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF)

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update

Safety and Efficacy of Ruxolitinib Retreatment after Treatment Interruption in Patients Enrolled in an Open-Label, Multicenter, Expanded-Access Study in Myelofibrosis

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis

Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis (MF)

Barriers To Diagnosis In Myeloproliferative Neoplasms

Improved Survival with Iron Chelation Therapy for Lower IPSS Risk MDS Appears to Have a Stronger Association in Patients with a Non-RARS Diagnosis

Clinical Features, Treatment, and Outcome of Severe HIV-Associated Immune Thrombocytopenic Purpura In the HAART Era

Diagnosis and Treatment of Essential Thrombocythemia: Assessment of Current Clinical Practice.

Thrombotic Complications and Risk of Myeloid Transformation in 164 Elderly Patients with Essential Thrombocythemia.

A Scoring System Based on Clinical, Blood Count and Immunophenotypic Data Can Predict the Risk of Disease Progression in Patients with Chronic Lymphocytic Leukemia

CD38 Expression above 20% Predicts Disease Progression in Chronic Lymphocytic Leukemia and Is a Useful Prognostic Marker Where Cytogenetic and Molecular Markers Are Not Available

Richter Transformation of Chronic Lymphocytic Leukemia: Incidence, Risk Factors and Outcome

Improved Survival in Red Blood Cell Transfusion Dependent Patients with Primary Myelofibrosis (PMF) Receiving Iron Chelation Therapy.

Who Actually Detects Relapse in Hodgkin Lymphoma: Patient or Physician?.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only